Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A daily 15 mg dose of the oral medication pazopanib for patients with age-related macular degeneration (AMD, a leading cause of blindness) resulted in improvements in vision and other measures related to the retina, according to a report of two clinical trials by Megan M. McLaughlin, M.S., of GlaxoSmithKline, King of Prussia, Pa., and colleagues.
Most of the vision loss caused by AMD is connected to new blood vessel formation in the retina, according to the study background. Treatment with a drug that blocks new blood vessel formation is effective but must be given by injection in the eye. Pazopanib is a new drug that blocks blood vessel formation that can be given by mouth.
The clinical trials included 72 healthy controls and 15 patients with AMD. Healthy participants were administered 5 to 30 mg of oral pazopanib daily and patients with AMD were given 15 mg daily.
According to the findings, oral pazopanib (15 mg daily) was well tolerated and resulted in improvements in vision, according to the study.
"Based on safety and preliminary efficacy, these studies identified a dose of oral pazopanib that may be appropriate for further investigation in patients with neovascular AMD," the authors conclude. This was a phase 1 trial intended to establish a dose with acceptable efficacy and safety that could be studied more intensively.
The study was financially supported by GlaxoSmithKline. Some authors are also the company’s employees.
JAMA Ophthalmol - Published online October 10, 2013. doi:10.1001/.jamaopthalmol.2013.5002
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Eye Health / Blindness category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Ophthalmology, JAMA. "Clinical trial examines oral supplementation in age-related macular degeneration." Medical News Today. MediLexicon, Intl., 11 Oct. 2013. Web.
12 Dec. 2013. <http://www.medicalnewstoday.com/releases/267273>
Ophthalmology, J. (2013, October 11). "Clinical trial examines oral supplementation in age-related macular degeneration." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/267273.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.